Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

MedImmune and Mirati to conduct trial combining durvalumab and mocetinostat

Aug. 5, 2015

Anti-GD2 antibody enters phase II trial in osteosarcoma

Aug. 3, 2015

Perjeta regimen approved in E.U. for use before surgery in early-stage breast cancer

Aug. 3, 2015

arGEN-X and University of Bern to develop ARGX-110-based combination therapies

Aug. 3, 2015

Scancell and ImmunID to use ImmunTraCkeR to predict response to SCIB-1

July 31, 2015

FDA clears KaloBios' IND for KB-003 for chronic myelomonocytic leukemia

July 30, 2015

Inovio Pharmaceuticals begins trial of INO-5150 for prostate cancer

July 30, 2015

Fujifilm Kyowa Kirin Biologics establishes joint venture with AstraZeneca

July 29, 2015

Horizon collaborates with Fox Chase to study Actimmune with PD-1/PD-L1 inhibitors for cancer

July 29, 2015

TapImmune exercises option agreement for folate receptor alpha vaccine technology

July 28, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...